Bremelanotide
Approved in the US only for women; never approved for men.
A peptide that acts on arousal pathways in the brain, not on blood flow. It grew out of melanotan II and is approved in the US only for women. Online it is sold to men as PT-141. A made by Cosette (developed by Palatin), also called PT-141 and Vyleesi.
What the evidence shows
Side effects and risks
Who should avoid it: Uncontrolled high blood pressure, heart disease, and daily use.
How it works
- Where it acts
- Melanocortin receptors in the brain, mainly MC4.
- What it changes
- It is thought to act on desire pathways in the brain, though the exact mechanism is unknown. It is not a blood-flow drug like erection pills.
- What people notice
- A modest rise in sexual desire in trials. Nausea is common, and blood pressure rises for up to about 12 hours.
How it is taken
A 1.75 mg injection under the skin at least 45 minutes before sex. At most one dose in 24 hours and eight a month.
Getting it in the United States
The legal route for Bremelanotide
Get a prescription from a licensed clinician. Fill it at a licensed pharmacy or through the maker's own direct service.
Prescription, including telemedicine
Vyleesi is a prescription self-injection approved for premenopausal women with low sexual desire. The current owner also offers a telemedicine route to a prescriber. Use in men or as PT-141 from other channels is outside the approval.
Source: Business Wire, 2024-01
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
What users report
Recurring themes in public forum posts, unverified and with no comparison group.
Reported benefits
- Noticeable arousal within a few hours
Reported problems
- Nausea, sometimes strong
- Flushing and headache
- Works one time and not the next
The nausea reports match the label closely.
More contextWhat public figures say, videos and articles, when options run out and the chemistry
What experts and influencers say
Paraphrased from the linked sources.
Told STAT that the modest trial results are meaningful to her patients with low sexual desire.
Source: STAT, 2019-06
Sheryl KingsbergWebsiteRecommends
Money: Led bremelanotide studies and was a paid adviser to the then marketer
Photo source: myalloy.com
Judges each peptide separately. He sees no use case for BPC-157: no human evidence, animal data mostly from one lab, and claims that keep widening. He is not a proponent of growth-hormone peptides such as CJC-1295, citing short studies and no long-term safety data. He says elamipretide makes sense only for Barth syndrome, that the risks of melanotan II probably outweigh a cosmetic tan, and that he stopped prescribing bremelanotide. He regards the GLP-1 drugs as clearly effective.
Peter AttiaInstagramMixed view
Argued that treating low desire with a drug applies the wrong model to sexuality, which she does not see as a single medical function.
Source: STAT, 2019-06
Leonore TieferWebsiteWarns against
Dismissed the dispute over whether low desire is a medical condition as an old argument no longer worth having.
Source: STAT, 2019-06
Sharon ParishWebsiteRecommends
Money: Paid adviser to the then marketer
Photo source: theswell.com
Doubted the drug would earn outsized revenue, because it is unclear how many women with low desire seek treatment.
Source: STAT, 2019-06
Photo source: marketbeat.com
Described Vyleesi as a useful as-needed option that women can give themselves, and encouraged women with low desire to raise treatment with a clinician.
Source: Business Wire, 2024-01
Rachel RubinInstagramRecommends
Money: Quoted in the new owner's press release
Sold Vyleesi to refocus on the pipeline. Annual sales were about 12.5 million dollars, far below an analyst forecast of 108 million for 2025 made at approval.
Source: Fierce Pharma, 2023-12
Carl SpanaSourceMixed view
Money: Company sold Vyleesi for 12 million dollars upfront plus sales milestones
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
Women's Wellness: Libido drug to help women with low sexual desire
Dr Stephanie Faubion, Director of Mayo Clinic's Center for Women's Health
A Mayo physician explains that Vyleesi acts on brain chemistry rather than blood flow, is not a female Viagra, and is used on demand.
Clear clinician explanation of the approved version.
Benefits & Risks of Peptide Therapeutics for Physical & Mental Health
Dr Andrew Huberman, Stanford neuroscientist
A late chapter covers melanotan and PT-141 (Vyleesi) under vitality peptides, with warnings about side effects and risks.
Puts PT-141 in context with other peptides, risks included.
When options run out
Uses people turn to when standard treatment has failed.
Add-on to tirzepatide for obesity
- Who
- People with obesity in a company trial testing whether a melanocortin drug adds to a GLP-1 class medicine.
- Evidence
- The developer announced in 2025 that a phase 2 study met its goal. Company-reported only. An earlier analysis found lower calorie intake in obese women.
- Route
- Company phase 2 trial, completed 2025
Source: PharmaCompass news index, 2025
Erectile dysfunction alongside a PDE5 inhibitor
- Who
- Men with erectile dysfunction. Earlier nasal trials in men were halted in 2007 over raised blood pressure.
- Evidence
- Four older company trials, the last a phase 2b published in 2008. A new phase 2 combination study was announced in 2024. No approval for men.
- Route
- Company phase 2 trial
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Amino-acid sequence
Positions 2 and 7 are joined by a side-chain ring, closing a ring. Striped tiles are mirror-image (D) amino acids, which resist breakdown. Ringed tiles are amino acids not found in natural proteins.
Questions people ask
Does PT-141 work for men?
It was never approved for men. Small placebo-controlled lab studies of a nasal spray showed erectile responses, but development of the spray stopped in 2007 over rises in blood pressure.
How is bremelanotide different from erection pills?
It acts on melanocortin receptors in the brain and is not a blood-flow drug like erection pills. It is thought to act on desire pathways, though the exact mechanism is unknown.
How well does Vyleesi work for women?
The effect is small: desire scores rose 0.5 to 0.6 points against 0.2 on placebo, and the number of satisfying sexual events did not change. It was approved in the US in 2019 for premenopausal women with low desire.
What are the side effects of PT-141?
Nausea affects 40% of users, and about one in eight needed anti-nausea medicine. Flushing (20%), headache, a rise in blood pressure for up to 12 hours, and dark patches on the face, gums or breasts that may not fade are also reported.
Is PT-141 legal?
In the US it is approved only as the Vyleesi autoinjector for premenopausal women with hypoactive sexual desire disorder, and FDA named PT-141 in warning letters to research-use-only sellers in August 2026. No EU authorization or UK license was found.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
- Vyleesi US prescribing information (DailyMed)
- Diamond et al. 2004: intranasal PT-141 in men
- ArentFox Schiff: FDA letters to research-use-only vendors (Sep 2026)
Structure: PubChem